• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC TO-I/A filed by BlackRock Technology and Private Equity Term Trust

    7/9/25 3:02:17 PM ET
    $BTX
    Get the next $BTX alert in real time by email
    SC TO-I/A 1 d39166dsctoia.htm SC TO-I/A SC TO-I/A
     
     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE TO

    TENDER OFFER STATEMENT

    Under Section 14(d)(1) or 13(e)(1)

    of the Securities Exchange Act of 1934

    (Amendment No. 1)

     

     

    BlackRock Technology and Private Equity Term Trust

    (Name of Subject Company (Issuer))

    BlackRock Technology and Private Equity Term Trust

    (Names of Filing Person(s) (Issuer))

    Common Shares of Beneficial Interest, Par Value $0.001 per share

    (Title of Class of Securities)

    09260Q108

    (CUSIP Number of Class of Securities)

    John M. Perlowski

    BlackRock Technology and Private Equity Term Trust

    50 Hudson Yards

    New York, New York 10001

    (800) 882-0052

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Person(s))

     

     

    Copies to:

     

    Margery K. Neale, Esq.   Janey Ahn, Esq.
    Elliot J. Gluck, Esq.   BlackRock Advisors, LLC
    Willkie Farr & Gallagher LLP   50 Hudson Yards
    787 Seventh Avenue   New York, New York 10001
    New York, New York 10019  

    June 9, 2025

    (Date Tender Offer First Published, Sent or Given to Security Holders)

     

     

     

    ☐

    Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

    Check the appropriate boxes below to designate any transactions to which this statement relates:

     

      ☐

    third-party tender offer subject to Rule 14d-1.

      ☒

    issuer tender offer subject to Rule 13e-4.

      ☐

    going-private transaction subject to Rule 13e-3.

      ☐

    amendment to Schedule 13D under Rule 13d-2.

    Check the following box if the filing is a final amendment reporting the results of the tender offer. ☐

     

     
     


    This Amendment No. 1 (“Amendment No. 1”) amends and supplements the Issuer Tender Offer Statement on Schedule TO filed on June 9, 2025 (the “Schedule TO”) by BlackRock Technology and Private Equity Term Trust, a Maryland statutory trust (the “Fund”), pursuant to Rule 13e-4 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), in connection with an offer by the Fund (the “Offer”) to repurchase 50% of its issued and outstanding common shares of beneficial interest, par value $0.001 per share (the “Shares”), in exchange for cash at a price equal to 99.5% of the net asset value (“NAV”) per Share determined as of the close of the regular trading session of the New York Stock Exchange, the principal market on which the Shares are traded, on the next day the NAV is calculated after the Offer expires, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated June 9, 2025 (the “Offer to Purchase”), and in the related Letter of Transmittal, copies of which were previously filed as Exhibits (a)(1)(i) and (a)(1)(ii), respectively, to the Schedule TO.

    This Amendment No. 1 is being filed to update Item 12 of the Schedule TO to include a press release announcing the preliminary results of the Offer, which expired on July 8, 2025, at 11:59 p.m. Eastern time. A copy of the press release is attached hereto as Exhibit (a)(5)(ii).

    Except as specifically provided herein, the information contained in the Schedule TO, the Offer to Purchase and the Letter of Transmittal remains unchanged, and this Amendment No. 1 does not modify any of the information previously reported in the Schedule TO, the Offer to Purchase or the Letter of Transmittal.

    Item 1 through Item 9 and Item 11

    The information set forth in the Offer to Purchase and the related Letter of Transmittal is incorporated by reference into this Amendment No. 1 in answer to Item 1 through Item 9 and Item 11 of the Schedule TO.

     

    Item 10.

    Financial Statements

    (a) The audited annual financial statements of the Fund dated December 31, 2024 and the schedule of investments of the Fund dated December 31, 2024, both filed with the SEC on EDGAR on Form N-CSR on March 7, 2025, are incorporated by reference.

    (b) Not applicable.

     

    Item 12(a).

    Exhibits

    Item 12(a) of the Schedule TO is hereby amended and supplemented to add the following exhibit:

    (a)(5)(ii)   Press release issued on July 9, 2025 is filed herewith.

     

    Item 12(c).

    Filing Fees

    Filing Fee Exhibit is filed herewith.

     

    Item 13.

    Information Required By Schedule 13E-3

    Not applicable.

     

    - 2 -


    SIGNATURE

    After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    BlackRock Technology and Private Equity Term Trust
    By:  

    /s/ John M. Perlowski

      Name: John M. Perlowski
      Title: President and Chief Executive Officer
      Dated: July 9, 2025

     

    - 3 -


    Exhibit Index

     

    Exhibit
    Number
     

    Description

    (a)(5)(ii)   Press release issued on July 9, 2025
      Filing Fee Exhibit

     

    - 4 -

    Get the next $BTX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BTX

    DatePrice TargetRatingAnalyst
    12/29/2021$9.00Overweight
    Cantor Fitzgerald
    10/6/2021$20.00Buy
    Maxim Group
    More analyst ratings

    $BTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Brooklyn with a new price target

      Cantor Fitzgerald initiated coverage of Brooklyn with a rating of Overweight and set a new price target of $9.00

      12/29/21 7:03:49 AM ET
      $BTX
    • Maxim Group initiated coverage on Brooklyn ImmunoTherapeutics with a new price target

      Maxim Group initiated coverage of Brooklyn ImmunoTherapeutics with a rating of Buy and set a new price target of $20.00

      10/6/21 7:53:44 AM ET
      $BTX

    $BTX
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13D/A filed by BlackRock Technology and Private Equity Term Trust

      SCHEDULE 13D/A - BlackRock Technology & Private Equity Term Trust (0001836057) (Subject)

      7/11/25 5:12:41 PM ET
      $BTX
    • Amendment: SEC Form SC TO-I/A filed by BlackRock Technology and Private Equity Term Trust

      SC TO-I/A - BlackRock Technology & Private Equity Term Trust (0001836057) (Subject)

      7/9/25 8:45:39 PM ET
      $BTX
    • Amendment: SEC Form SC TO-I/A filed by BlackRock Technology and Private Equity Term Trust

      SC TO-I/A - BlackRock Technology & Private Equity Term Trust (0001836057) (Subject)

      7/9/25 3:02:17 PM ET
      $BTX

    $BTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Saba Capital Management, L.P. disposed of $454,458,709 worth of shares (60,675,395 units at $7.49) (SEC Form 4)

      4 - BlackRock Technology & Private Equity Term Trust (0001836057) (Issuer)

      7/10/25 3:48:00 PM ET
      $BTX
    • New insider Minar Stephen Thomas claimed ownership of 1,967 shares (SEC Form 3)

      3 - BlackRock Technology & Private Equity Term Trust (0001836057) (Issuer)

      5/16/25 4:24:38 PM ET
      $BTX
    • SEC Form 3 filed by new insider Cicala Peter

      3 - Eterna Therapeutics Inc. (0000748592) (Issuer)

      2/16/24 5:30:35 PM ET
      $BTX

    $BTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BlackRock Technology and Private Equity Term Trust (BTX) Announces Final Results of Tender Offer

      BlackRock Technology and Private Equity Term Trust (the "Fund") announced today the final results of the Fund's tender offer (the "Tender Offer") for up to 50% of its outstanding common shares (the "Shares"), which expired on July 8, 2025. The Tender Offer was undersubscribed. Therefore, in accordance with the terms and conditions of the Tender Offer, the Fund will purchase all Shares properly tendered from all tendering shareholders. Payment for Shares tendered and accepted are expected to be made approximately five business days after the pricing date (anticipated to be July 16, 2025). The final results of the Tender Offer are provided in the table below: Fund Name Ticker

      7/9/25 8:41:00 PM ET
      $BTX
    • BlackRock Technology and Private Equity Term Trust (BTX) Announces Expiration and Preliminary Results of Tender Offer

      BlackRock Technology and Private Equity Term Trust (the "Fund") announced today the expiration and preliminary results of the Fund's tender offer (the "Tender Offer") for up to 50% of its outstanding common shares (the "Shares"). The Tender Offer commenced on June 9, 2025 and expired at 11:59 p.m. Eastern time on July 8, 2025. Based on preliminary information, the number of Shares properly tendered and not withdrawn is noted in the table below. Fund Name Ticker CUSIP Shares Offered for Repurchase Shares Tendered (Preliminary Results) BlackRock Technology and Private Equity Term Trust BTX 09260Q108 106,669,074 96,627,850

      7/9/25 8:58:00 AM ET
      $BTX
    • Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds

      Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: Declaration- 7/1/2025 Ex-Date- 7/15/2025 Record- 7/15/2025 Payable- 8/1/2025     National Funds     Ticker     Distribution Change From Prior Distribution   BlackRock Municipal Income Quality Trust*   BYM   $0.055500   - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock Investment Qu

      7/1/25 6:02:00 PM ET
      $BBN
      $BCAT
      $BCX
      $BDJ
      Finance Companies
      Finance
      Finance/Investors Services
      Trusts Except Educational Religious and Charitable

    $BTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Brooklyn ImmunoTherapeutics Inc. (Amendment)

      SC 13G/A - Eterna Therapeutics Inc. (0000748592) (Subject)

      1/31/24 7:05:56 AM ET
      $BTX
    • SEC Form SC 13G/A filed by Brooklyn ImmunoTherapeutics Inc. (Amendment)

      SC 13G/A - Eterna Therapeutics Inc. (0000748592) (Subject)

      1/19/24 10:31:54 AM ET
      $BTX
    • SEC Form SC 13D/A filed by Brooklyn ImmunoTherapeutics Inc. (Amendment)

      SC 13D/A - Eterna Therapeutics Inc. (0000748592) (Subject)

      12/22/23 12:05:20 PM ET
      $BTX

    $BTX
    Financials

    Live finance-specific insights

    See more
    • Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds

      Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: Declaration- 7/1/2025 Ex-Date- 7/15/2025 Record- 7/15/2025 Payable- 8/1/2025     National Funds     Ticker     Distribution Change From Prior Distribution   BlackRock Municipal Income Quality Trust*   BYM   $0.055500   - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock Investment Qu

      7/1/25 6:02:00 PM ET
      $BBN
      $BCAT
      $BCX
      $BDJ
      Finance Companies
      Finance
      Finance/Investors Services
      Trusts Except Educational Religious and Charitable
    • Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions

      Today, BlackRock Resources & Commodities Strategy Trust (NYSE:BCX), BlackRock Enhanced Equity Dividend Trust (NYSE:BDJ), BlackRock Energy and Resources Trust (NYSE:BGR), BlackRock Enhanced International Dividend Trust (NYSE:BGY), BlackRock Health Sciences Trust (NYSE:BME), BlackRock Health Sciences Term Trust (NYSE:BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE:BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE:BUI), BlackRock Enhanced Large Cap Core Fund, Inc. (NYSE:CII), BlackRock Science and Technology Trust (NYSE:BST), BlackRock Science and Technology Term Trust (NYSE:BSTZ), BlackRock Technology and Private Equity Term Trust (NYSE:BTX), BlackRock Capital

      6/30/25 4:31:00 PM ET
      $BBN
      $BCAT
      $BCX
      $BDJ
      Finance Companies
      Finance
      Finance/Investors Services
      Trusts Except Educational Religious and Charitable
    • Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds

      Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: Declaration- 6/2/2025   Ex-Date- 6/13/2025   Record- 6/13/2025   Payable- 7/1/2025   National Funds    Ticker Distribution Change From Prior Distribution BlackRock Municipal Income Quality Trust*  BYM  $0.055500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock Investment Quality Municipal Trust, Inc.* BKN

      6/2/25 5:27:00 PM ET
      $BBN
      $BCAT
      $BCX
      $BDJ
      Finance Companies
      Finance
      Finance/Investors Services
      Trusts Except Educational Religious and Charitable

    $BTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual Meeting

      SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn" or the "Company"), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Matt Angel, Ph.D., Co-Founder, Chairman, and CEO of Factor Bioscience Inc., as Interim Chief Executive Officer and President. He will replace Howard J. Federoff, M.D., Ph.D., Chief Executive Officer and President, who departs to focus on building a new venture. The Company also announces the appointment of Andrew Jackson as Chief

      5/31/22 7:30:00 AM ET
      $BTX
    • Amarin Announces Appointment of New Directors and Board Leadership Changes

      Erin Enright and Alfonso "Chito" Zulueta Appointed to Board of Directors New Board Members Bring Skills and Experience Aligned with the Company's Strategy Per Wold-Olsen Named Chairman of the Board David Stack and Joe Zakrzewski to Retire from the Board Actions Reflect Company and Board's Commitment to Ongoing Refreshment and Enhancement DUBLIN, Ireland and BRIDGEWATER, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced a series of appointments and leadership changes to its Board of Directors, including: Appointment of Erin Enright and Alfonso "Chito" Zulueta to the Board, effective immediately. Ms. Enright and Mr. Zulueta will sta

      5/19/22 8:23:13 AM ET
      $AMRN
      $BTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Redman to Its Board of Directors

      NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces the appointment of two new members of the Company's Board of Directors. Erin S. Enright has served on multiple Boards of Directors, including within the medical and life sciences arenas, such as Keystone Dental (serving as Audit Committee Chair), Medical Facilities Corporation (serving as Audit and Investment Committee Chair), and Dynatronics Corporation (serving on the Audit, Compensati

      1/20/22 7:30:00 AM ET
      $BTX